CooperCompanies’ (NYSE:COO) CooperSurgical business has purchased Aegea Medical, nearly a year after Aegea secured FDA approval for its Mara water vapor ablation system for treating heavy menstrual bleeding. The financial terms of the deal were not disclosed in the companies’ announcement yesterday. The companies pointed out an international, multi-center pivotal clinical trial enrolling 155 women, […]
The Cooper Cos.
CooperVision wins FDA approval for myopia contact lens for kids
CooperVision (NYSE:COO) said that it won FDA approval for its MiSight one-day contact lens for slowing the progression of myopia when initially prescribed for children between 8-12 years old. The San Ramon, Calif.–based company announced the clearance for the first and only FDA-approved product clinically proven to slow myopia (nearsightedness or short-sightedness) yesterday. CooperVision said […]
FDA approves CooperVision’s contact lens to slow nearsightedness in kids
The FDA has approved the first contact lens indicated to slow the progression of nearsightedness in children between the ages of 8 and 12 years old. The MiSight contact by CooperCompanies’ (NYSE:COO) CooperVision lens is a single-use, disposable, soft contact lens that is discarded at the end of each day and is not intended to be worn […]
Cooper Cos. shares rise on FY2019 Q1 earnings beat
Shares in Cooper Cos. (NYSE:COO) have risen in after-hours trading today after the company reported first quarter fiscal year 2019 earnings that beat expectations on Wall Street. The Pleasanton, Calif.-based company reported profits of $103.2 million, or $2.07 per share, on sales of $628.1 million for the three months ended January 31, seeing a swing […]
Teva closes Paragard sale to CooperSurgical
Teva Pharmaceuticals (NYSE:TEVA) said today that it closed the $1.1 billion cash sale of its Paragard intrauterine copper contraceptive device to Cooper Cos.‘ (NYSE:COO) CooperSurgical unit. The deal included Teva’s manufacturing facility in Buffalo, N.Y., the pharma company reported. The move is part of Teva’s efforts to restructure its business, narrowing its focus on CNS and respiratory […]
Teva deals Paragard IUD assets to Cooper Cos. for $1B
Cooper Cos. (NYSE:COO) said today it inked a deal to purchase the Paragard intrauterine device assets and business, including a Buffalo, N.Y.-based factory, from Teva Pharmaceuticals (NYSE:TEVA) for $1.1 billion in cash. The deal has been unanimously approved by both Teva and The Cooper Co.’s boards of directors, and is expected to close prior to the end of 2017, […]
Smiths Medical deals Wallace IVF biz to CooperSurgical for $174m
Smiths Group (LON:SMIN) said today it divested its Wallace in-vitro fertilization product line to Cooper Cos. (NYSE:COO) CooperSurgical subsidiary for $174 million (UK £140 million). The divestiture is part of an ongoing program at Smiths to focus its portfolio on “market leading positions of scale in its chosen markets,” the company said. The company said that proceeds from […]
CooperVision, EP Global go their separate ways in contact lens deal
EP Global Communications (OTC:EPGL) said it’s parting ways with Cooper Cos. (NYSE:COO) subsidiary CooperVision on a co-development project for advanced contact lens technology. Irvine, Calif.-based EP Global, which last year threw the gauntlet before Google (NSDQ:GOOG) on its much-ballyhooed smart contact lens program, said the Dec. 31 settlement with CooperVision allows each company to pursue the technology on its […]
CooperSurgical pays $47m for IVF screener Reprogenetics
Cooper Cos. (NYSE:COO) CooperSurgical subsidiary acquired in-vitro fertilization screening company Reprogenetics last week for nearly $47 million. Livingston, N.J.-based Reprogenetics offers pre-implantation genetic screening and diagnosis for in vitro fertilization, Cooper said. The $46.5 million deal isn’t expected to affect earnings per share this year or in 2016, but should be accretive thereafter, the company said. Reprogenetics put up […]
Covidien hunts for new CFO | Personnel Moves
Covidien (NYSE:COV) said it’s searching for a new CFO after Charles Dockendorff announced his plans to retire from the company at the end of 2014.
Dockendorff has been with the company since 1989, serving in a variety of finance-related roles. He was named CFO of Covidien predecessor Tyco Healthcare in 1995, helping lead the company to $10 billion in sales in 2007.
